Supplemental Figure Legends Supplemental Figure 1a: SF-36. SF-36 mental component score among subjects randomized to SAMe or placebo, at baseline, Week.

Slides:



Advertisements
Similar presentations
Supplemental Figure 1 A No. at risk T T T
Advertisements

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.
Copyright © 2012 Lippincott Williams & Wilkins. Unauthorized commercial reproduction of this slide is prohibited Supplemental PowerPoint Slides Acupuncture.
WEEK 1 You have 10 seconds to name…
Date of download: 5/27/2016 Copyright © 2016 American Medical Association. All rights reserved. From: A Randomized, Placebo-Controlled, Clinical Trial.
Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Quality of Life After PCI vs CABG Among Patients.
Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effectiveness of Foot Orthoses to Treat Plantar Fasciitis:
Date of download: 6/3/2016 From: The Effect of Erythropoietin-Stimulating Agents on Health-Related Quality of Life in Anemia of Chronic Kidney Disease:
Date of download: 6/9/2016 From: Escitalopram for the Prevention of Peginterferon-α2a–Associated Depression in Hepatitis C Virus– Infected Patients Without.
Opiate Therapy in Chronic Cough Alyn H. Morice, Madhav S. Menon, Siobhan A. Mulrennan, Caroline F. Everett, Caroline Wright, Jennifer Jackson and Rachel.
Date of download: 6/24/2016 From: Effectiveness of Manual Physical Therapy and Exercise in Osteoarthritis of the Knee: A Randomized, Controlled Trial Ann.
Date of download: 6/24/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Aripiprazole, an Antipsychotic With a Novel Mechanism.
Date of download: 7/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: A Randomized, Placebo-Controlled, Clinical Trial of.
Date of download: 7/6/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effect of Duloxetine on Pain, Function, and Quality.
Date of download: 9/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Use of Pattern Analysis to Predict Differential Relapse.
Date of download: 9/20/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of a Palliative Care Intervention on Clinical.
Copyright © 1998 American Medical Association. All rights reserved.
Copyright © 2003 American Medical Association. All rights reserved.
From: Recombinant Leptin for Weight Loss in Obese and Lean AdultsA Randomized, Controlled, Dose-Escalation Trial JAMA. 1999;282(16): doi: /jama
From: A Randomized Trial Comparing Acupuncture, Simulated Acupuncture, and Usual Care for Chronic Low Back Pain Arch Intern Med. 2009;169(9): doi: /archinternmed
Copyright © 2014 American Medical Association. All rights reserved.
Copyright © 2015 by the American Osteopathic Association.
Volume 42, Issue 5, Pages (May 2005)
Randomization to a low-carbohydrate diet advice improves health related quality of life compared with a low-fat diet at similar weight-loss in Type 2.
Copyright © 2004 American Medical Association. All rights reserved.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2004 American Medical Association. All rights reserved.
Copyright © 2006 American Medical Association. All rights reserved.
Copyright © 2003 American Medical Association. All rights reserved.
دانشیار دانشکده دندانپزشکی دانشگاه علوم پزشکی شهید صدوقی یزد
Proportion of patients reporting scores ≥age-matched and gender-matched normative PRO values at baseline and 24 weeks in the (A) AMBITION and (B) ADACTA.
ODYSSEY LONG TERM Trial design: Participants with heterozygous familial hypercholesterolemia or high CV risk on statin therapy were randomized to alirocumab.
Volume 147, Issue 6, Pages e3 (December 2014)
Change in secondary endpoints over time: (A) LS mean change from baseline in DAS28-CRP through Week 32, (B) mean change from baseline in CRP through Week.
Mean change in patient-reported outcomes from baseline to Week 25 with biweekly or monthly pegloticase compared with placebo. Mean change in patient-reported.
Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated.
ODYSSEY FH I and II Trial design: Participants with heterozygous familial hypercholesterolemia on statin therapy were randomized to alirocumab 75 mg SQ.
Marlene H. Frost, RN, PhD, Amy E. Bonomi, MPH, PhD, Joseph C
Volume 61, Issue 5, Pages (November 2014)
Infliximab Prevents Crohn's Disease Recurrence After Ileal Resection
A randomized, double-blind, crossover study of the use of transcutaneous spinal electroanalgesia in patients with pain from chronic critical limb ischemia 
Virologic Response to Therapy Increases Health-Related Quality of Life for Patients With Chronic Hepatitis B  Jeong Han Kim, So Young Kwon, Young Sok.
Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A New Health-Related Quality-of-Life Instrument  Dorothee Oberdhan, Jason.
Volume 44, Issue 3, Pages (March 2006)
Issue Highlights Clinical Gastroenterology and Hepatology
Интерпретация және зерттеу нәтижесін өңдеу
Steven D. Targum, Christopher J. Catania 
Supplemental Figure 1A Pt Pt Pre-treatment
Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir  Zobair.
Effects of Sofosbuvir-Based Treatment, With and Without Interferon, on Outcome and Productivity of Patients With Chronic Hepatitis C  Zobair M. Younossi,
Effects of reslizumab on asthma control questionnaire-7 (ACQ-7) score in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of reslizumab.
Aimee L. Speck, MD, Michael Hess, MSI, Alan P. Baptist, MD, MPH 
Correlations between observed patient-reported outcomes and disease activity scores at week 24. Correlations between observed patient-reported outcomes.
REAL-WORLD SAFETY, EFFECTIVENESS, AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION TREATED WITH GLECAPREVIR/PIBRENTASVIR:
Emmanuel Chartier-Kastler, Kate Davidson  European Urology Supplements 
Volume 136, Issue 7, Pages (June 2009)
Clinical Gastroenterology and Hepatology
Volume 132, Issue 1, Pages (January 2007)
Laparoscopy vs. Robotic Surgery for Endometriosis (LAROSE): a multicenter, randomized, controlled trial  Enrique Soto, M.D., M.Sc., Thanh Ha Luu, M.D.,
The Journal of Allergy and Clinical Immunology: In Practice
Patient-reported outcomes: proportion of patients with clinically meaningful improvements in (A) SF-36 PCS and MCS at Week 52 and Week 104*†‡ and (B) HAQ-DI.
MOOD-HF Trial design: Patients with chronic systolic heart failure and comorbid depression were randomized to escitalopram (n = 185) vs. placebo (n = 187).
Assessed for eligibility (n=71)
Percentages of patients reporting improvements from baseline ≥minimum clinically important difference (MCID) and number needed to treat (NNT) in (A) patient-reported.
Volume 128, Issue 4, Pages (April 2005)
Volume 134, Issue 3, Pages (March 2008)
Spydergram of mean SF-36 domain scores at baseline and weeks 12 (A) and 24 (B) for sarilumab 150 mg and 200 mg+csDMARDs compared with placebo+csDMARDs.
Proportion of patients reporting improvements from baseline in patient-reported outcomes (PROs) ≥ the MCID at (A) 16 weeks in OPTION, (B) 12 weeks in BREVACTA.
Post hoc analysis of differences from placebo in the percentage of patients reporting improvements ≥MCID at week 24. Post hoc analysis of differences from.
Receiver operating characteristic (ROC) curves for Saint George’s Respiratory Questionnaire (SGRQ) category scores predicting chronic obstructive pulmonary.
Presentation transcript:

Supplemental Figure Legends Supplemental Figure 1a: SF-36. SF-36 mental component score among subjects randomized to SAMe or placebo, at baseline, Week 12 and Week 24. Supplemental Figure 1b: SF-36 physical component score among subjects randomized to SAMe or placebo, at baseline, Week 12 and Week 24. Only subjects with SF-36 at all three time points were included in the analysis. Supplemental Figure 2: CLDQ. Chronic liver disease questionnaire among subjects randomized to SAMe or placebo, at baseline, Week 12 and Week 24. Only subjects with CLDQ at all three time points were included in the analysis.

Supplemental Figure 1a

Supplemental Figure 1b

Supplemental Figure 2